CN109328196B - 识别TGFβRII的移码突变体的T细胞受体 - Google Patents

识别TGFβRII的移码突变体的T细胞受体 Download PDF

Info

Publication number
CN109328196B
CN109328196B CN201780038176.8A CN201780038176A CN109328196B CN 109328196 B CN109328196 B CN 109328196B CN 201780038176 A CN201780038176 A CN 201780038176A CN 109328196 B CN109328196 B CN 109328196B
Authority
CN
China
Prior art keywords
seq
ser
leu
cells
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780038176.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109328196A (zh
Inventor
E·M·因德贝格
G·高德纳克
S·瓦赤莉
G·科瓦尔海姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo Universitetssykehus hf
Original Assignee
Oslo Universitetssykehus hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Universitetssykehus hf filed Critical Oslo Universitetssykehus hf
Publication of CN109328196A publication Critical patent/CN109328196A/zh
Application granted granted Critical
Publication of CN109328196B publication Critical patent/CN109328196B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
CN201780038176.8A 2016-05-09 2017-05-09 识别TGFβRII的移码突变体的T细胞受体 Active CN109328196B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII
GB1608052.5 2016-05-09
PCT/EP2017/061087 WO2017194555A1 (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII

Publications (2)

Publication Number Publication Date
CN109328196A CN109328196A (zh) 2019-02-12
CN109328196B true CN109328196B (zh) 2022-11-01

Family

ID=56297359

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780038176.8A Active CN109328196B (zh) 2016-05-09 2017-05-09 识别TGFβRII的移码突变体的T细胞受体

Country Status (13)

Country Link
US (1) US20190336529A1 (enExample)
EP (1) EP3455249B1 (enExample)
JP (1) JP2019517790A (enExample)
KR (1) KR20190016507A (enExample)
CN (1) CN109328196B (enExample)
AU (1) AU2017261684A1 (enExample)
CA (1) CA3024555A1 (enExample)
EA (1) EA201892217A1 (enExample)
GB (1) GB201608052D0 (enExample)
IL (1) IL262873A (enExample)
MX (1) MX2018013581A (enExample)
SG (1) SG11201809716VA (enExample)
WO (1) WO2017194555A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724043B2 (en) * 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3692058A1 (en) * 2017-10-06 2020-08-12 Oslo Universitetssykehus HF Chimeric antigen receptors
SG11202102903QA (en) 2018-09-21 2021-04-29 Xlifesc Ltd High affinity t cell receptor for recognizing afp antigen
US20220193137A1 (en) * 2019-04-04 2022-06-23 Umc Utrecht Holding B.V. Modified immune receptor constructs
GB201907663D0 (en) 2019-05-30 2019-07-17 Ab Mavatar Method for diagnosing colorectal cancer
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024263818A2 (en) * 2023-06-20 2024-12-26 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574922A (zh) * 2009-07-29 2012-07-11 葛兰素集团有限公司 抗tgf-beta受体ii型单结构域抗体
CN103732623A (zh) * 2011-06-03 2014-04-16 佐马技术有限公司 对TGF-β具有特异性的抗体
CN105008380A (zh) * 2012-12-06 2015-10-28 卡拉翰创新研究有限公司 缀合化合物
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
FR2779432A1 (fr) * 1998-06-08 1999-12-03 Transgene Sa Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574922A (zh) * 2009-07-29 2012-07-11 葛兰素集团有限公司 抗tgf-beta受体ii型单结构域抗体
CN103732623A (zh) * 2011-06-03 2014-04-16 佐马技术有限公司 对TGF-β具有特异性的抗体
CN105008380A (zh) * 2012-12-06 2015-10-28 卡拉翰创新研究有限公司 缀合化合物
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Enhanced expression and anti-tumour activity of T cells engineered to express a cysteine-modified TCR targeting a frameshift mutation in MSI-HI colorectal cancer;E.Inderberg-Suso et al.;《Cytotherapy》;20140430;第16卷(第4期);第S27-S28页 *
HNPCC大肠腺瘤及癌组织微卫星不稳定与TGFβRII表达的关系;耿洪刚等;《胃肠病学和肝病学杂质》;20080731;第17卷(第7期);第572-575页 *

Also Published As

Publication number Publication date
EP3455249A1 (en) 2019-03-20
WO2017194555A1 (en) 2017-11-16
GB201608052D0 (en) 2016-06-22
CA3024555A1 (en) 2017-11-16
EA201892217A1 (ru) 2019-08-30
US20190336529A1 (en) 2019-11-07
KR20190016507A (ko) 2019-02-18
EP3455249B1 (en) 2023-05-03
MX2018013581A (es) 2019-07-04
JP2019517790A (ja) 2019-06-27
AU2017261684A1 (en) 2018-12-13
CN109328196A (zh) 2019-02-12
IL262873A (en) 2019-01-31
SG11201809716VA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CN109328196B (zh) 识别TGFβRII的移码突变体的T细胞受体
US10822389B2 (en) Antibody/T-cell receptor chimeric constructs and uses thereof
KR102483822B1 (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2019525898A (ja) ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
JP2016525537A (ja) Ｔ細胞レセプター
JP2015521172A (ja) 親和性増強型ｔ細胞受容体およびその作製方法
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
JP2023525049A (ja) ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
WO2022098750A1 (en) Hla class ii-restricted tcrs against the kras g12&gt;v activating mutation
TWI843716B (zh) hTERT特異性結合分子
EP4491630A1 (en) T-cell receptor for acute myeloid leukemia (aml)
EA042909B1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
KR20240099260A (ko) 변형된 결합 단백질 및 이의 치료적 용도
Foley Structure-Guided T Cell Receptor Mutations that Alter Antigen Specificity, Cross-Reactivity, and Polyfunctional Phenotypes in Gene-Modified T Cells
HK40055433A (en) Antibody/t-cell receptor chimeric constructs and uses thereof
HK1258274B (en) Antibody/t-cell receptor chimeric constructs and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant